-
公开(公告)号：EP4401719A1
公开(公告)日：2024-07-24
申请号：EP22790264.0
申请日：2022-09-15
IPC分类号： A61K31/137 , A61K31/366 , A61K31/40 , A61K31/4439 , A61K31/496 , A61K31/5375 , A61K31/5377 , A61K33/243 , A61K45/06 , A61P35/00 , A61P35/04
CPC分类号： A61K31/496 , A61K31/5377 , A61K31/40 , A61K31/366 , A61K31/137 , A61K33/243 , A61K31/5375 , A61K31/4439 , A61K45/06 , A61P35/00 , A61P35/04
-
公开(公告)号：EP4151208A1
公开(公告)日：2023-03-22
申请号：EP21197506.5
申请日：2021-09-17
IPC分类号： A61K31/137 , A61K31/366 , A61K31/40 , A61K31/4439 , A61K31/496 , A61K31/5375 , A61K31/5377 , A61K33/243 , A61K45/06 , A61P35/00 , A61P35/04
摘要： The invention relates to novel compositions, combinations and methods relating to compounds which inhibit EZH2 and their uses for treating and/or preventing tumors associated with methyltransferase EZH2. More specifically the invention relates to synergistic bi-therapy compositions for use in a method of treating and/or preventing tumors associated with methyltransferase EZH2, comprising administering to a subject in need, a therapeutically effective amount of the composition, wherein said composition comprises the combination of EZH2 inhibitor and one HMG-CoA reductase inhibitor or statin. The present invention also relates to synergistic tri-therapy compositions as well as methods of use thereof for treating and/or preventing specific types of cancers and tumors comprising further administering an effective amount of one or more anticancer drugs or chemotherapeutic agents in combination with the above bi-therapy compositions.
-
3.发明公开
公开(公告)号：EP4330909A1
公开(公告)日：2024-03-06
申请号：EP22725731.8
申请日：2022-04-25
申请人： UNIVERSITE DE BORDEAUX , Institut National de la Santé et de la Recherche Médicale , Centre National de la Recherche Scientifique , Institut Polytechnique de Bordeaux
-
-
搜索结果
3 条记录 (耗时 0.015 秒)
